Market Newsdesk

NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kandi Technologies Group, Inc. (NASDAQ: KNDI) between March 15, 2019 and November 27, 2020, inclusive (the “Class Period”), of the important February 9, 2021 lead plaintiff deadline.

SO WHAT: If you purchased Kandi securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Kandi class action, go to http://www.rosenlegal.com/cases-register-1998.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 9, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Kandi artificially inflated its reported revenues through undisclosed related party transactions, or otherwise had relationships with key customers that indicated those customers did not have an arms-length relationship with Kandi; (2) the majority of Kandi’s sales in the past year had been to undisclosed related parties and/or parties with such a close relationship and history with Kandi that it cast doubt on the arms-length nature of their relationship; (3) all the foregoing, once revealed, was foreseeably likely to cast doubt on the validity of Kandi’s reported revenues and, in turn, have a foreseeable negative impact on the Company’s reputation and valuation; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Kandi class action, go to http://www.rosenlegal.com/cases-register-1998.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

To date, 84% of skilled nursing residents and 61% of skilled nursing staff have been vaccinated; Staff acceptance rates far exceed national average as reported by CDC

KENNETT SQUARE, Pa., Feb. 02, 2021 (GLOBE NEWSWIRE) — Genesis HealthCare, (“Genesis” or “Company”) (NYSE: GEN), one of the largest post-acute care providers in the United States, announced today that 84% of its skilled nursing residents and 61% of skilled nursing staff members have been vaccinated, each receiving their first dose of the COVID-19 vaccine, through January 29, 2021. Staff vaccine acceptance rates far exceed the national average, and resident acceptance rates at Genesis skilled nursing centers were also above the national average, based on vaccine administration data in an analysis published by the Centers for Disease Control and Prevention (CDC).

On February 1, 2021, the CDC announced that “among 11,460 SNFs with at least one vaccination clinic conducted during the first month of the CDC Pharmacy Partnership for Long-Term Care Program, a median of 77.8% of residents and 37.5% of staff members received ≥1 vaccine dose through the program.”

“I am so extraordinarily proud of the progress our centers have made vaccinating both residents and staff,” states Dr. Richard Feifer, Chief Medical Officer of Genesis. “Our leadership team, clinicians, physicians and advanced practice providers have been working around the clock to educate patients, residents, staff and families about the importance of being vaccinated, and to answer every point of hesitancy or concern with a combination of compassion and factual information. These acceptance rates are a testament to the hard work and dedication our leadership and center staff have shown throughout this entire pandemic. We are not done yet, and continue our work to increase vaccination rates even higher.”

As of January 21, 2021, 100% of Genesis skilled nursing facilities received dose one of the vaccine, primarily utilizing CVS Health, our primary partner through the Pharmacy Partnership for Long Term Care program. Genesis facilities were among the first to begin vaccinations in nursing homes, beginning on December 17, 2020. After the first clinic, the pharmacists return three to four weeks later to administer the second booster shots for those who received the vaccine in round one, and will also vaccinate anyone not included in round one. The pharmacists will then return for a third time, three to four weeks after round two, to administer the final booster shots. Genesis skilled nursing facilities are approximately 67% through their second clinics.

Genesis continues its robust communications and engagement initiatives to build trust among patients, residents, families and staff. Genesis has conducted ‘Ask the Doc’ sessions, social media campaigns, educational outreach, and a variety of other engagement tactics to promote vaccination. Multiple second clinics are ongoing every day and Genesis facilities are striving to get as many people vaccinated as quickly as possible at each clinic. The Company expects acceptance rates to continue to climb.

All drugs or vaccines have some potential side effects, and it is important to monitor for such issues even after a drug or vaccine is approved. Thus far, there have been minimal reported side effects after patients, residents and staff have received the vaccine. As the largest nursing home operator, Genesis is participating in a newly developed safety monitoring program with Brown University School of Public Health researchers, to monitor for any potential adverse health impacts after nursing home residents in our centers receive COVID-19 vaccinations. This work is part of a CDC effort to carefully monitor vaccine safety, particularly focused on frail elderly residents who were not included in vaccine trials.

About Genesis HealthCare

Genesis HealthCare is a holding company with subsidiaries that, on a combined basis, comprise one of the nation’s largest post-acute care companies, providing services to more than 325 skilled nursing facilities and assisted/senior living communities in 24 states nationwide. Genesis subsidiaries also supply rehabilitation therapy to approximately 1,100 healthcare providers in 44 states, the District of Columbia and China. References made in this release to “Genesis,” “the Company,” “we,” “us” and “our” refer to Genesis Healthcare, Inc. and each of its wholly-owned companies. Visit our website at www.genesishcc.com.

New York , Feb. 02, 2021 (GLOBE NEWSWIRE) — The Music Acquisition Corporation (the “Company”) today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. The units will be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “TMAC.U” beginning on February 3, 2021. Each unit consists of one share of Class A common stock and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one share of Class A common stock at a price of $11.50 per share. After the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on the NYSE under the symbols “TMAC” and “TMAC WS,” respectively. The offering is expected to close on February 5, 2021, subject to customary closing conditions.

The Music Acquisition Corporation is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any industry or geographic region, the Company intends to focus its search for an initial business combination on businesses that are either directly or indirectly connected with the music sector, with particular emphasis on businesses where the Company’s significant strategic and operational expertise and long-standing position within the music industry will be a value-additive proposition to potential target businesses. The Company is led by Chairman and Chief Executive Officer Neil Jacobson and Chief Operating Officer Todd Lowen. In addition to Messrs. Jacobson and Lowen, the Company’s Board of Directors includes Michael Levitt, Ben Silverman, and Tunde Balogun.   

Citigroup Global Markets Inc. and Cantor Fitzgerald & Co. are acting as joint bookrunning managers for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 units at the initial public offering price to cover over-allotments, if any.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering is being made only by means of a prospectus. When available, copies of the prospectus relating to the offering may be obtained from Citigroup Global Markets Inc., Attention: Prospectus Department, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; and Cantor Fitzgerald & Co., Attention: Prospectus Group, 499 Park Avenue, New York, NY 10022, or by telephone at (1-212) 915-1067 or by email at [email protected].

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the initial public offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contact:

Neil Jacobson
[email protected]
(747) 203-7219

# # #

WILMINGTON, Del., Feb. 02, 2021 (GLOBE NEWSWIRE) —

Rigrodsky Law, P.A. announces that it is investigating Kismet Acquisition One Corp. (“Kismet”) (NASDAQ GS: KSMT) regarding possible breaches of fiduciary duties and other violations of law related to Kismet’s agreement to merge with Nexters Global Limited.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-kismet-acquisition-one-corp.

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected].

Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:         

Rigrodsky Law, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
[email protected]
https://rl-legal.com

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) — Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced the addition of Shao-Lee Lin, M.D., Ph.D. to the Board of Directors. Dr. Lin is currently co-founder and chief executive officer at ACELYRIN, INC.

“Dr. Lin’s scientific insights, broad therapeutic area experience, deep intellect and commitment to developing breakthrough therapies is the ideal alignment with our mission and strategy,” said Craig Parker, president and chief executive officer at Surrozen. “Our novel approach to selectively harness the potential of the Wnt pathway has far-reaching therapeutic potential and I look forward to Dr. Lin’s contributions directing our platform and technologies to the most promising areas.”

Dr. Lin is an accomplished physician-scientist with over 20 years of academic and clinical research experience. Prior to her role as ACELYRIN’s chief executive officer, Dr. Lin previously served as executive vice president, head of R&D, and chief scientific officer at Horizon Therapeutics, where she built and led the R&D organization that advanced new treatments for patients with rare diseases. Prior to Horizon, Dr. Lin was a corporate officer leading therapeutic areas, development excellence, and international development at AbbVie. Dr. Lin earlier served as VP, Inflammation and Respiratory Development at Gilead and was responsible for multiple therapeutic areas at Amgen.

“Surrozen and its founders have made important contributions to understanding the potential of the Wnt pathway for tissue repair and regeneration. The promise of Wnt biology across a multitude of diseases has been evident for some time and I’m excited by the opportunity to help guide the innovation that Surrozen’s Wnt platform represents,” said Dr Lin.

Dr. Lin received her undergraduate degree in chemical engineering and biochemistry from Rice University. She received her M.D. and Ph.D. degrees at the Johns Hopkins University School of Medicine and held postdoc fellowships in Rheumatology, Allergy, and Immunology at UCSD and The Scripps Clinic and Research Institute. Throughout her career, Dr. Lin has held clinical and teaching appointments, first as Clinical Scholar at The Rockefeller University and adjunct faculty in Medicine at Cornell, and subsequently at UCLA, Stanford, and Northwestern.

About Surrozen

Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. For more information, please visit surrozen.com.

Investors/Partners/Media:

Reza Afkhami
VP, Corporate Development and Strategy
Surrozen, Inc.
[email protected]

ATHENS, Greece, Feb. 02, 2021 (GLOBE NEWSWIRE) — Growth Capital Acquisition Corp. (NASDAQ: GCACU) (“Growth Capital” or the “Company”) today announced the closing of its initial public offering of 17,250,000 units, which included 2,250,000 units sold upon the full exercise of the underwriters’ over-allotment option, at a price of $10.00 per unit, resulting in total gross proceeds of $172.5 million. The units commenced trading on the Nasdaq Capital Market (“Nasdaq”) on January 29, 2021 under the symbol “GCACU”. Each unit consisted of one share of Class A common stock and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable. Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be traded on the Nasdaq under the symbols “GCAC” and “GCACW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

Maxim Group LLC acted as sole book-running manager for the offering. Roth Capital Partners acted as the qualified independent underwriter for the offering.

A registration statement relating to the securities was declared effective by the SEC on January 29, 2021. The offering was made only by means of a prospectus, copies of which may be obtained by contacting Maxim Group LLC, 405 Lexington Avenue, New York, New York 10174. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Growth Capital Acquisition Corp.

Growth Capital is a Delaware blank check company, also commonly referred to as a Special Purpose Acquisition Company (or SPAC), formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. The Company’s efforts to identify a target business will not be limited to a particular industry or geographic region. Growth Capital is led by Co-Chief Executive Officers Akis Tsirigakis and George Syllantavos and Maxim Group LLC and received financial backing from HB Strategies LLC, an affiliate of Hudson Bay Capital Management LP.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including the anticipated use of the net proceeds. No assurance can be given that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and the final prospectus for the offering filed with the Securities and Exchange Commission (“SEC”). Copies will be available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.